At some point, nearly everyone experiences the uncomfortable feeling of dry eyes. However, for some, it may become an ongoing condition that requires treatment. At Cosmopolitan Eyecare, we are proud to offer the first and only IPL FDA-approved treatment for dry eye disease, OptiLight.
What is Dry Eye?

Dry eye, also known as ocular surface disease, is a common condition that occurs when your eyes do not produce enough lubrication. Fatty oils, water, and mucus create a complex mixture that helps to maintain a healthy surface for your eyes to provide you with clear vision.

The cause of dry eyes can be varied. Tear production may decrease as a result of the natural aging process, hormonal changes, environmental conditions, inflammation, medication, and other medical conditions.

Take Our Dry Eye Quiz

What is OptiLight?

OptiLight is an IPL, or intense pulsed light, treatment designed to improve the symptoms of dry eye disease and lipid deficiency dry eye. During treatment, the patient will wear protective eyewear as the treatment is delivered to the upper cheek area, under the eyes, and around the nose. Treatment breaks up any blockages in glands and abnormal blood vessels causing inflammation.

The benefits of OptiLight treatment includes:

  • Alleviating abnormal blood vessels
  • Decreasing Demodex mites
  • Improving tear breakup time
  • Reducing inflammatory mediators
  • Restoring meibomian glands
Each OptiLight session lasts 15 minutes making it brief enough to be squeezed into a busy day if needed. During your consultation, we will determine how many treatment sessions you will need based on your condition. On average, we recommend 4-6 treatment sessions.

Possible side effects can include pain, scarring, burns, and bruising as well as damage to surrounding skin such as changes in pigmentation.

At Cosmopolitan Eyecare, we are honored to serve patients in our community with dry eyes. For more information on OptiLight and our services or to schedule an appointment, contact our office today at (212) 302-4889.